Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Hawaii Health Digest.
Press releases published on August 7, 2025
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 2025 2025 Wells Fargo …
Kura Oncology Reports Second Quarter 2025 Financial Results
– FDA Priority Review of New Drug Application (NDA) for ziftomenib in adults with R/R NPM1-m AML with Prescription Drug User Fee Act (PDUFA) target action date set for November 30, 2025 – – Fully engaged in commercial readiness activities in alignment with …
Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post …
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025 China and European approval for zanidatamab in 2L HER2-positive biliary tract …
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. …
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- …
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via RaniPill (RT-114) compared to …
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the second quarter ended June 30, …
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted EPS of $0.03, and Adjusted EBITDA of …
BeautyHealth Reports Second Quarter 2025 Financial Results
Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster LONG BEACH, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: …
RxSight, Inc. Reports Second Quarter 2025 Financial Results
ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for …
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it …
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – …
Apyx Medical Expands Global Sales Leadership with Strategic Hires to Support AYON Launch and Accelerated Growth
CLEARWATER, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation, an advanced energy technology company and manufacturer of Renuvion® and the newly launched AYON Body Contouring System™, today announced the strategic appointments of two …
Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results
CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and …
Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC
6-month follow-up for NDV-01 showed a 91% overall response rate at any time in non-muscle invasive bladder cancer, with good overall safety Enrollment in the Phase 2 study for NDV-01 continues, with updates expected at 9 and 12 month data follow-up. …
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform …
Scientific Industries Completes Strategic Refocus and Secures Proceeds of $10 million to Accelerate Growth of Two Data-Driven Business Platforms; Divests Genie® Division to OHAUS Corporation’s affiliate Troemner, LLC
Realign priorities - AI-powered platforms to accelerate innovation and market leadership Driving transformation in pharmacy automation with VIVID’s advanced solutions Advancing AI-powered biomanufacturing with SBI’s DOTS Platform BOHEMIA, N.Y., Aug. 07, …